Early Real-World Outcomes with Filgotinib in Patients with Ulcerative Colitis: A Prospective, Observational Study (GALOCEAN)
October 2024
This study investigates the real-world effectiveness of Filgotinib (FIL), an oral JAK1 preferential inhibitor, in patients with ulcerative colitis (UC). While the clinical efficacy of FIL has been established in the SELECTION trial, real-world data has been limited.
The first interim report of the GALOCEAN study presents week 10 results, showing that FIL significantly improves UC symptoms, health-related quality of life, and reduces fatigue in real-world clinical practice. As the study is ongoing, long-term data with a larger patient cohort will further assess the real-world effectiveness of FIL in UC.